CJC-1295 DAC
Research OnlyModified GRF 1-29 (DAC)
CJC-1295 DAC is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) modification binds reversibly to albumin, extending the peptide’s half-life to approximately 6–8 days. By stimulating pituitary GHRH receptors, CJC-1295 DAC increases GH secretion and circulating IGF-1 in a dose-dependent manner.
Dosing Schedule
| Week | Dose | Units (U-100) |
|---|---|---|
| 1-2 | 300 mcg | 12 units |
| 3-4 | 500 mcg | 20 units |
| 5-6 | 750 mcg | 30 units |
| 7-12 | 1000 mcg | 40 units |
Frequency: Inject twice weekly subcutaneously (e.g., Monday/Thursday).
When you BUY CJC-1295 DAC, you want to know that it's pure. We recommend using trusted suppliers for your research needs.
Visual representation of the dosage ramp-up over the cycle duration.
Reconstitution
2ml
2.5 mg/mL
5 mg
Add 2.0 mL bacteriostatic water to a 5 mg vial to achieve a concentration of 2.5 mg/mL (2500 mcg/mL).
Administration
Timing Strategy
Consistent timing (e.g., evenings); rotate injection sites.
Cycle Length
8–12 weeks; optional extension to 16 weeks.
Research Benefits
Supports sustained elevation of GH and IGF-1. May promote increased lean body mass, reduced fat mass, and improved body composition. Enhanced protein synthesis and recovery potential.
Storage Guidelines
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable for 2–4 weeks. Avoid freeze–thaw cycles.
Research Purposes Only
This information is for educational and research purposes only. These compounds are not approved for human consumption. Always consult with a qualified professional and adhere to local regulations regarding research chemicals.
Concentration
2.50 mg/mL
(2500 mcg/mL)
Injection Volume
0.10 mL
Draw to this mark on U-100 Syringe
Visual representation on a standard U-100 Insulin Syringe